Literature DB >> 18248717

PET/CT fusion technology: its role in managing recurrent, well-differentiated thyroid cancer.

Dustin Dalgorf1, Kevin M Higgins, Lisa Ehrlich.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18248717      PMCID: PMC2386302     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


× No keyword cloud information.
  5 in total

1.  Intraoperative electrophysiologic monitoring of the recurrent laryngeal nerve.

Authors:  D W Eisele
Journal:  Laryngoscope       Date:  1996-04       Impact factor: 3.325

2.  Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.

Authors:  B Schlüter; K H Bohuslavizki; W Beyer; M Plotkin; R Buchert; M Clausen
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

3.  The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma.

Authors:  Zayna Nahas; David Goldenberg; Carol Fakhry; Marjorie Ewertz; Martha Zeiger; Paul W Ladenson; Richard Wahl; Ralph P Tufano
Journal:  Laryngoscope       Date:  2005-02       Impact factor: 3.325

4.  Image analysis in patients with cancer studied with a combined PET and CT scanner.

Authors:  M Charron; T Beyer; N N Bohnen; P E Kinahan; M Dachille; J Jerin; R Nutt; C C Meltzer; V Villemagne; D W Townsend
Journal:  Clin Nucl Med       Date:  2000-11       Impact factor: 7.794

5.  Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer.

Authors:  Lee A Zimmer; Barry McCook; Carolyn Meltzer; Melanie Fukui; Daphne Bascom; Carl Snyderman; David W Townsend; Jonas T Johnson
Journal:  Otolaryngol Head Neck Surg       Date:  2003-02       Impact factor: 3.497

  5 in total
  1 in total

Review 1.  Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management.

Authors:  M Naji; M Hodolic; S El-Refai; S Khan; M C Marzola; D Rubello; A Al-Nahhas
Journal:  J Endocrinol Invest       Date:  2009-10-09       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.